The drugs for arthritis and heart disease can also treat COVID-19?
- The first Alzheimer’s disease Aβ and Tau pathological surrounding cell structure and gene expression map
- Magic TCR-T cell therapy: 72% of tumor lesions disappeared
- Monkeypox mRNA Vaccine Competition: U.S. vs. China
- Can an universal mRNA flu vaccine be against all 20 virus subtypes?
- Harvard found why high-protein diet improves sleep quality
- Will cancer vaccines be the direction of curing cancer?
The drugs for arthritis and heart disease can also treat COVID-19?
- The first DMD gene therapy SRP-9001 may cost 4 million US dollars
- COVID-19 has been confirmed to cause DNA damage and cellular aging
- First human trial of HIV gene therapy: A one-time cure will be achieved if successful!
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
The drugs for arthritis and heart disease can also treat COVID-19?
According to a Reuters report on September 10, researchers recently discovered that an anti-inflammatory drug, Anakinra, used to treat rheumatoid arthritis, static disease and recurrent fever, can significantly reduce severe illness. The risk of death in patients with COVID-19.
The research results have been published in the top academic journal “Nature Medicine” (impact factor of 36.130 in 2019). Researchers found that among 594 patients with COVID-19, compared with patients taking placebo, the risk of death for those receiving anakinra treatment was generally reduced by 55% to 80%.
(Picture from Nature Medicine)
“From the 14th day, the clinical benefits of anakinra treatment have been very obvious, and the benefits of the drug can continue until the 28th day,” but the researchers pointed out that the use of anakinra to guide the COVID-19 Treatment may be problematic because not every hospital can provide tests for related drugs.
In addition, new data shows that drugs that usually prevent thrombosis after arterial clearing surgery can also prevent thrombosis in patients with COVID-19 disease-an article was published in the academic journal “Science Advances” on September 8. (The impact factor for 2020 is 14.14) The paper stated that the anticoagulant drugs clopidogrel and ticagrelor can effectively prevent the excessive activation of platelets in patients with COVID-19 disease to form thrombus.
(Picture from Science Advances)
According to Reuters, Bristol-Myers Squibbl and Sanofi are currently selling clopidogrel under the trade name Plavix. And AstraZeneca has already started selling Tegrelor under the brand name Brilinta.
The author of the paper said that if more studies can prove this discovery, these drugs may “become a particularly attractive therapy for reducing inflammatory thrombosis caused by the new coronavirus.”
(source:internet, reference only)
Disclaimer of medicaltrend.org
